Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
复制标题
DOI：
10.1186/1475-2840-9-17
复制
发表时间：
2010-05-14
影响因子：
9.3
通讯作者：
Izumi, Tohru
中科院分区：
文献类型：
--
作者：
Yamaoka-Tojo, Minako;Tojo, Taiki;Izumi, Tohru
背景：胰高血糖素样肽-1 (GLP-1) 是一种肠促胰岛素激素，对葡萄糖代谢和心血管功能具有广泛的影响（例如，提高胰岛素敏感性、降低食欲、调节心率、血压和心肌收缩力）。代谢综合征（MetS）与患动脉粥样硬化性心血管疾病的风险增加有关。新型血糖控制药物二肽基肽酶 4 (DPP-4) 抑制剂通过抑制肠促胰岛素激素、GLP-1 和葡萄糖依赖性促胰岛素多肽 (GIP) 的失活发挥作用。尽管这些药物对糖尿病患者有良好的疗效，但肠促胰岛素的循环水平及其在 MetS 中的作用在很大程度上尚不清楚。 方法：为了检查肠促胰岛素激素与 MetS 危险因素之间的关系，我们测量了肥胖心血管疾病高危患者的肠促胰岛素的循环水平。通过ELISA测定空腹血清GLP-1和GIP水平。我们对两个受试者组的空腹状态下的代谢变量进行了横断面分析：MetS 组 (n = 60) 和 MetS 前组 (n = 37)。 结果：外周循环中血清 GLP-1 的空腹水平显着升高，与 MetS 危险因素成分的积累相关 (r = 0. 470, P < 0.001)。循环 GLP-1 和 GIP、血清高密度脂蛋白胆固醇、甘油三酯和血清尿酸浓度之间存在显着的相互作用，但与腰围、空腹血糖、HbA1c 或是否存在糖尿病无关。结论：循环 GLP-1 水平与 MetS 因子积累相关，表明 GLP-1 水平升高的 MetS 患者是心血管疾病的高危患者，与是否存在糖尿病无关。
Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has a wide range of effects on glucose metabolism and cardiovascular function (e. g., improving insulin sensitivity, reduction in appetite, modulation of heart rate, blood pressure and myocardial contractility). Metabolic syndrome (MetS) is associated with an increased risk of developing atherosclerotic cardiovascular diseases. Novel glycemic control drugs, the dipeptidyl-peptidase-4 (DPP-4) inhibitors, work by inhibiting the inactivation of incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role in MetS are largely unknown.Methods: To examine relationships between incretin hormones and MetS risk factors, we measured circulating levels of incretins in obese high-risk patients for cardiovascular disease. Fasting serum GLP-1 and GIP levels were measured by ELISA. We performed a cross-sectional analysis of metabolic variables in the fasting state in two subject groups: with MetS (n = 60) and pre-MetS (n = 37).Results: Fasting levels of Serum GLP-1 in the peripheral circulation were significantly increased correlated with the accumulation of MetS risk factors components (r = 0. 470, P < 0.001). There was a significant interaction between circulating GLP-1 and GIP, serum high-density lipoprotein cholesterol, triglyceride, and serum uric acid concentrations but not waist circumference, fasting glucose, HbA1c, or presence of diabetes.Conclusion: Circulating levels of GLP-1 in relation to the accumulation in MetS factors suggested that MetS patients with elevated levels of GLP-1 are high-risk patients for cardiovascular disease, independent with the presence of diabetes.